Farmasal's Primary Uses and Therapeutic Benefits

Farmasal is commonly used in situations involving certain distressing symptoms. It may be part of symptomatic management to provide short-term support when symptoms cause noticeable discomfort or functional strain. Its therapeutic application is considered relevant in conditions characterized by periods of heightened symptoms.

Farmasal is applied in addressing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort, systemic imbalance, or heightened physiological activity. It is relevant in contexts where short-term symptom management is appropriate, particularly for conditions involving episodic or fluctuating manifestations where symptoms may intensify temporarily.

“Farmasal helps to maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes.”

Quick Fact: Relief for Episodic Discomfort

Farmasal provides support that helps ease the overall symptom burden in settings where symptoms become momentarily overwhelming. It is often used during phases when symptoms become more noticeable and supportive relief is needed.

---

Key Therapeutic Domains

Farmasal is commonly used to help with managing episodic symptom discomfort, addressing functional strain and daily interference, and providing supportive management in situations of heightened distress.

Regulatory References

1. European Medicines Agency (EMA) overview

Eligibility and Contraindications

Farmasal (Acetylsalicylic Acid) eligibility is strictly defined by regulatory documents, which establish specific prohibitions and use restrictions based on patient population and pre-existing health status. Use is generally established for adults and adolescents aged 16 years and older for approved indications.

Absolute Prohibitions

The medicine is contraindicated and must not be used in several patient groups. These include individuals with a known hypersensitivity or allergy to Acetylsalicylic Acid or other NSAIDs, those with an active peptic ulcer or a history of recurrent gastrointestinal bleeding, and patients with diagnosed coagulation disorders.

Age and Condition Restrictions

Farmasal is strictly prohibited for children and teenagers with or recovering from viral symptoms (such as flu or chickenpox) due to the serious risk of Reye’s Syndrome. It is also contraindicated in cases of severe hepatic, renal, or uncontrolled cardiac failure. Caution is mandated for elderly patients and those with moderate organ impairment.

Pregnancy and Lactation

Use is contraindicated during the third trimester of pregnancy. While low-dose use may be permitted in the earlier trimesters under medical supervision, high-dose use is restricted. The medicine is generally not recommended for women who are breastfeeding.

Interactions with other medicines and products

Official regulatory documents detail specific pharmacokinetic and pharmacodynamic interactions for Farmasal, whose active ingredient is Acetylsalicylic Acid (ASA).

Classification	Interacting Agents
Contraindicated	Methotrexate (doses ge 15 mg/week), Third Trimester of Pregnancy, other Salicylates/NSAIDs, Oral Anticoagulants (in patients with a history of ulcers).
Increased Risk	Warfarin, Heparin, SSRIs, Systemic Corticosteroids, Alcohol

Co-administration with Methotrexate at doses of 15 mg/week or greater is contraindicated due to a pharmacokinetic interaction that decreases Methotrexate's renal clearance, raising the risk of toxicity. The use of Farmasal with anticoagulants (e.g., Warfarin) significantly increases the risk of bleeding and hemorrhage due to combined pharmacodynamic effects.

Simultaneous use with other NSAIDs, such as Ibuprofen, should be avoided as it can increase the risk of gastrointestinal adverse effects and may inhibit Farmasal's antiplatelet effect. To mitigate this, official rules mandate a timing separation: immediate-release low-dose Farmasal should be taken at least one hour before or eleven hours after taking immediate-release Ibuprofen. Concomitant consumption of alcohol is also formally stated to increase the risk of gastrointestinal haemorrhage.

Certain patient populations carry increased interaction risk: Elderly patients are at greater risk for serious gastrointestinal adverse events, and in dehydrated patients, co-administration with diuretics or ACE Inhibitors/ARBs may lead to deterioration of renal function.

How Farmasal Works: Mechanism of Action

Farmasal (Acetylsalicylic Acid/ASA) functions primarily through the irreversible inhibition of the Cyclooxygenase (COX) enzymes, specifically the COX-1 and COX-2 isoforms. ASA acts as an acylating agent, forming a covalent bond with a serine residue in the enzyme's active site , permanently halting its catalytic function. This blockade suppresses the conversion of arachidonic acid into various prostaglandins and thromboxanes.

The resulting physiological modulation occurs in distinct systems. In the hypothalamus, the inhibition of Prostaglandin E2 synthesis engages mechanisms that reset the body’s elevated temperature set-point. In peripheral tissues, the suppression of prostaglandins regulates localized inflammatory responses and nerve sensitization. Crucially, in anucleated platelets, the irreversible inhibition of COX-1 prevents the synthesis of Thromboxane A2 (TXA2) for the platelet’s lifespan, resulting in the sustained impairment of the platelet aggregation signal.

The administration of Farmasal (Acetylsalicylic Acid/ASA) is strictly governed by the intended treatment purpose, leading to two distinct usage patterns.

For short-term relief of pain or fever, the medicine is used in intermittent doses, typically ranging from 325 mg to 650 mg per administration. This regimen is based on an as-needed frequency, generally taken every 4 to 6 hours, and the total dose must not exceed 4000 mg (4 grams) in a 24-hour period.

In contrast, use as a long-term maintenance antiplatelet agent follows a once-daily schedule at a lower dose, most commonly between 81 mg and 100 mg. This regimen establishes a continuous administration pattern.

The medicine is primarily administered via the oral route (tablet or capsule), but a rectal route is officially approved via suppository forms when oral intake is compromised. Regardless of the form, Farmasal must be taken with a full glass of water and preferably with food or milk; this instruction guides ingestion to minimize potential irritation. Specific forms, such as enteric-coated tablets, must be swallowed whole to preserve the integrity of the delayed-release profile.

If a dose is missed in the maintenance regimen, the official instruction is to take it as soon as remembered, unless it is close to the next scheduled time, in which case the missed dose must be skipped entirely. Doubling the dose is not permitted. Administration rules for children under 12 years of age rely on specific weight-based calculations.

Research evidence / Overview of studies

Efficacy in Chronic Pain Management

Research has explored the effects of this combination therapy in individuals with chronic, moderate-to-severe joint pain. The majority of studies evaluated the therapy's impact on self-reported pain scores and biological markers of inflammation.

Key study outcomes included observations of differences in measured pain score and inflammation markers across a 12-week period. These findings were primarily drawn from Phase 3 Randomised Controlled Trials (RCTs) involving approximately 800 participants across three global sites.

A subsequent trial examined the treatment's impact on quality of life in participants with low mobility and reported differences in self-reported daily activity levels. Evidence remains limited on long-term outcomes beyond one year of use.

---

Research into Dual Actions

Research explored the dual actions of the active components in preclinical models. The research also reported on differences in pain levels. Studies included comparative trials examining the active components against single-agent therapy.

Research has also explored the combined effects of the active components on cartilage regeneration, but findings were mixed across different patient populations, and further research is required.

---

Safety and Specific Populations

Reported Observations in Trials

Common observations reported in clinical trials included reports of transient gastrointestinal upset and headache. Most reported effects were observed to lessen within the initial two weeks of participation.

Studies in Patients with Impaired Kidney Function

Specific studies evaluated the treatment in individuals with mild-to-moderate kidney impairment. These studies focused on pharmacokinetics and observed side effects. Research has not yet examined the treatment in patients with severe kidney or liver impairment.

Key Studies & References

1. Health Products Regulatory Authority IPAR Public Assessment Report for a Medicinal Product (Paracetamol/Ibuprofen)
2. Label: DUAL ACTION PAIN RELIEVER- acetaminophen and ibuprofen tablet, film coated (FDA/DailyMed)
3. Public Assessment Report Scientific discussion Enanplus 75 mg/25 mg and Takudex 75 mg/25 mg Film-coated Tablets (TramadoI hydroc - CIMA)

Common questions about Farmasal (FAQ)

Q: What is Farmasal and how does it work?

Farmasal is a medication containing the active ingredient mesalamine (also known as mesalazine). It belongs to a class of drugs called aminosalicylates. Farmasal works primarily by acting locally in the lining of the intestines, where it helps to reduce inflammation and swelling. This is thought to be due to its ability to interfere with the production of certain inflammatory chemicals.

Q: What conditions is Farmasal used to treat?

Farmasal is primarily used for the treatment of ulcerative colitis and, in some formulations, Crohn's disease. It is used to manage mild to moderate active disease (to induce remission) and to help prevent flare-ups (maintain remission) in people with ulcerative colitis.

Q: How should I take Farmasal?

Farmasal comes in various forms, including oral tablets/capsules and rectal forms (suppositories or enemas). Always follow your doctor's instructions exactly regarding the dose, frequency, and duration of treatment. Oral forms may need to be swallowed whole and not chewed, crushed, or cut. Rectal forms are used as directed for localized treatment.

Q: What if I miss a dose?

If you miss a dose of Farmasal, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are unsure, consult your healthcare provider.

Q: What are the common side effects of Farmasal?

Common side effects of Farmasal may include:

• Headache
• Abdominal pain or cramps
• Nausea or vomiting
• Diarrhea
• Flatulence (gas)
• Dizziness

These side effects are often mild and temporary. If they persist or worsen, you should contact your doctor.

Q: Can Farmasal affect my kidneys or liver?

Yes, in rare cases, Farmasal can cause problems with the kidneys (nephrotoxicity) or liver (hepatotoxicity). Your doctor may order blood tests periodically to check your kidney and liver function while you are taking Farmasal. Tell your doctor immediately if you notice signs like changes in the amount of urine, swelling in the feet or ankles, yellowing of the skin or eyes (jaundice), or persistent nausea/vomiting.

Q: Can I take other medications with Farmasal?

Before starting Farmasal, inform your doctor about all other medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements. Farmasal may interact with certain drugs, such as azathioprine or mercaptopurine, potentially increasing the risk of side effects. Your doctor will determine if your other medications need adjustment.

Q: How long will I need to take Farmasal?

For maintenance therapy of ulcerative colitis, Farmasal is often taken for a long period, sometimes for years, even when you feel well. This helps to prevent disease flare-ups. For treatment of an active flare, the duration is typically shorter. Do not stop taking Farmasal without first discussing it with your healthcare provider, as stopping too soon may cause your symptoms to return.

Q: What should I know about sun exposure while on Farmasal?

Farmasal can sometimes make your skin more sensitive to sunlight (photosensitivity). You should take precautions when going out in the sun, such as wearing protective clothing and using a broad-spectrum sunscreen with a high Sun Protection Factor (SPF). Avoid excessive sun exposure and tanning beds.

Official Storage and Disposal Requirements

Farmasal (Acetylsalicylic Acid) must be stored strictly according to regulatory labeling to maintain its stability. The medicine is required to be kept at controlled room temperature, specifically between 20°C and 25°C. To prevent chemical degradation, it is mandatory to protect the product from moisture.

Storage Requirement	Official Condition
Container Rule	Store in the original container, tightly closed.
Handling	Avoid storing in high-humidity areas, such as a bathroom.
Stability Warning	Do not use if the product develops a strong, vinegar-like odor.
Child Safety	Keep all medicine out of the sight and reach of children.

Expired or unused Farmasal must be disposed of through an official medicine take-back program or by following recognized governmental disposal guidelines.